Biomx Inc
PHGE0.393USD
-0.010-2.46%
Close 11/10, 16:00（ET）Quotes delayed by 15 min
10.39MMarket Cap
LossP/E TTM
More Details of Biomx Inc Company
BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
Biomx Inc Info
Ticker SymbolPHGE
Company nameBiomx Inc
IPO dateDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Number of employees52
Security typeOrdinary Share
Fiscal year-endDec 18
Address22 Einstein St.
CityNESS-ZIONA
Stock exchangeNYSE American Consolidated
CountryIsrael
Postal code7414003
Phone972723942377
Websitehttps://www.biomx.com/
Ticker SymbolPHGE
IPO dateDec 18, 2018
CEOMr. Jonathan Eitan Solomon
Company Executives of Biomx Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
111.35K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Dr. Jesse Goodman, M.D.
Dr. Jesse Goodman, M.D.
Independent Director
Independent Director
--
--
Dr. Russell G. Greig, Ph.D.
Dr. Russell G. Greig, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Eddie Williams
Mr. Eddie Williams
Independent Director
Independent Director
--
--
Mr. Gregory Merril
Mr. Gregory Merril
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jonathan Eitan Solomon
Mr. Jonathan Eitan Solomon
Chief Executive Officer, Director
Chief Executive Officer, Director
179.80K
--
Dr. Merav Bassan, Ph.D.
Dr. Merav Bassan, Ph.D.
Chief Development Officer
Chief Development Officer
111.35K
--
Ms. Marina Wolfson, CPA
Ms. Marina Wolfson, CPA
Chief Financial Officer
Chief Financial Officer
68.92K
--
Ms. Susan Blum, CPA
Ms. Susan Blum, CPA
Independent Director
Independent Director
--
--
Mr. Jonathan S. Leff
Mr. Jonathan S. Leff
Independent Director
Independent Director
--
--
Dr. Alan Charles Moses, M.D.
Dr. Alan Charles Moses, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Fri, Nov 7
Updated: Fri, Nov 7
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
9.39%
Cystic Fibrosis Foundation
9.39%
Nantahala Capital Management, LLC
9.39%
Morgan Stanley & Co. LLC
6.98%
Centaurus Investments Limited
4.03%
Other
60.81%
Shareholders
Shareholders
Proportion
Deerfield Management Company, L.P.
9.39%
Cystic Fibrosis Foundation
9.39%
Nantahala Capital Management, LLC
9.39%
Morgan Stanley & Co. LLC
6.98%
Centaurus Investments Limited
4.03%
Other
60.81%
Shareholder Types
Shareholders
Proportion
Hedge Fund
24.92%
Corporation
13.42%
Research Firm
8.61%
Holding Company
4.03%
Venture Capital
3.76%
Investment Advisor/Hedge Fund
2.34%
Individual Investor
1.46%
Investment Advisor
0.09%
Other
41.37%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
38
10.55M
39.72%
-5.15M
2025Q2
48
19.36M
73.97%
+6.20M
2025Q1
47
17.95M
68.92%
+5.32M
2024Q4
47
13.90M
76.65%
+2.77M
2024Q3
43
13.00M
74.85%
+8.58M
2024Q2
33
4.45M
66.70%
+1.05M
2024Q1
34
2.97M
56.90%
+586.97K
2023Q4
35
2.25M
51.72%
+502.58K
2023Q3
39
1.91M
46.61%
-56.19K
2023Q2
39
1.94M
47.21%
+273.60K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Deerfield Management Company, L.P.
2.49M
9.39%
--
--
Jun 30, 2025
Cystic Fibrosis Foundation
2.49M
9.39%
+706.35K
+39.51%
Feb 27, 2025
Nantahala Capital Management, LLC
2.49M
9.39%
--
--
Jun 30, 2025
Morgan Stanley & Co. LLC
1.85M
6.98%
+1.85M
--
Jun 30, 2025
Centaurus Investments Limited
1.07M
4.03%
+1.07M
--
Apr 21, 2025
Ikarian Capital LLC
892.98K
3.36%
--
--
Jun 30, 2025
AMR Action Fund LP
876.89K
3.3%
+571.40K
+187.05%
Sep 30, 2024
Telmina Ltd
560.27K
2.11%
+276.30K
+97.30%
Sep 30, 2024
Nimble Ventures LLC
510.20K
1.92%
+1.00
+0.00%
Sep 30, 2024
J.P. Morgan Securities LLC
430.00K
1.62%
--
--
Jun 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Date
Type
Ratio
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
Aug 15, 2024
Merger
10→1
